Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

0.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Jack Russell

Mammon

travisnye

To: dirkdiggler who wrote (12091)	6/13/2013 3:43:00 PM
From: Mimbari	3 Recommendations Read Replies (2) of 13111

Well I asked those that know something in the industry about regional deals. Here is impression I got. Big pharmas do want bolt-on's because they are poor at picking a good drug. They have been getting burned. Counter intuitively they are all saying they would rather make less and allow regional deals done than take the risk of buying early. Unbelievably they don't care. its a big company mentality. No matter how much the company stands to make off a drug they (the managers) still get paid the same. So all the decision makers in big pharma wish to protect their jobs and as a result will not move on global unless one of two things happen: (1.) The drug gets into phase III or (2.) another company tries to buy them (They do not want to look bad at letting a good drug go to the competition). About the delay. Its my impression that they had to wait on Moffit for the independent clarity. The blog recently touches on this. Now that they got the data they can go forward finally. The train is now moving again. Management and assertions: They said the drug works and it does. Your contention is about the delays. Most of their delays are out of their hands. Lets look back at AA at the end of Phase II. Back then the FDA gave indications that they may give AA. Then there was a big change-up in personnel after a big newspaper wrote on how bad drugs got approved. The new group that was in charge of approvals decided that AA is not a good thing at that point. Now that the FDA got a look at the Moffit data (independent), they are suggesting the BTD. Agree with you on the fact that the maximum share price cannot be achieved until there is a 100% buyout. I might add that to also get a maximum share price then this company needs to be on Nasdaq for the purpose of getting the stock up to say $20 before a buyout offer. Regional deal or BTD should do that.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next